Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters

Combining AstraZeneca plc's AZN COVID-19 vaccine with a second dose from either Pfizer Inc PFE - BioNTech SE BNTX or Moderna Inc's MRNA shot provides "good protection," Denmark's State Serum Institute (SSI) said.
More than 144,000 Danish citizens, mostly healthcare frontline personnel and the elderly, received their first jab from AstraZeneca and subsequent shot from either Pfizer-BioNTech or Moderna, reports Reuters.
"The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated individuals," the SSI said.
That is a "high efficacy," SSI added, comparable to the 90% efficacy rate of two doses from Pfizer-BioNTech's vaccine, confirmed in a different Danish study. But the study could not conclude whether the same protection applied to the Delta-variant.
It also provided no efficacy data on COVID-19 related deaths or hospitalizations since none took place following the combined vaccination program.
Price Action: AZN shares are up 0.31% at $57.42 on the last check Monday.
Photo by Johaehn from Pixabay